<DOC>
	<DOCNO>NCT00861640</DOCNO>
	<brief_summary>Introduction : Proton pump inhibitor ( PPI ) drug choice use patient non-variceal upper gastrointestinal tract bleeding ( UGIB ) . Intravenous ( IV ) PPI commonly use oral form overt bleeding occur . Previous study reveal oral rabeprazole IV omeprazole achieve similar intragastric pH elevation . It 's probable oral form IV PPI provide equal efficacy treat mild moderate UGIB patient . Aim : This study aim compare effect three-day oral rabeprazole iv omeprazole bleed control patient mild moderate non-variceal UGIB . Patients method : All patient present black tarry stool passage hematemesis visit ER evaluate recruit study . They receive regular vital sign monitoring , laboratory study nasogastric tube insertion gastric fluid aspiration . Esophagogastroendoscopy hemostatic procedure need perform within 12 hour . Those confirmed non-variceal UGIB , stable vital sign agree participate study randomize two group receive either oral rabeprazole ( 20mg bid ) iv omeprazole ( 40mg qd ) three day . The presence recurrent bleed within three day , in-hospital complication duration hospital stay record analyze . Expected result : At end study , able determine whether patient treated oral rabeprazole iv omeprazole similar re-bleeding complication rate hospitalization day .</brief_summary>
	<brief_title>Comparison Oral Rabeprazole vs. iv Omeprazole Mild Moderate Nonvariceal Upper Gastrointestinal Bleeding</brief_title>
	<detailed_description>Proton pump inhibitor ( PPI ) drug choice use patient non-variceal upper gastrointestinal tract bleeding ( UGIB ) . Intravenous ( IV ) PPI commonly use oral form overt bleeding occur . Previous study reveal oral rabeprazole IV omeprazole achieve similar intragastric pH elevation . It 's probable oral form IV PPI provide equal efficacy treat mild moderate UGIB patient . This study aim compare effect three-day oral rabeprazole iv omeprazole bleed control patient mild moderate non-variceal UGIB . The expected number intravenous oral PPI 100 respectively . All patient present black tarry stool passage hematemesis visit ER evaluate recruit study . They receive regular vital sign monitoring , laboratory study nasogastric tube insertion gastric fluid aspiration . Esophagogastroendoscopy hemostatic procedure need perform within 12 hour . Those confirmed non-variceal UGIB , stable vital sign agree participate study randomize two group receive either oral rabeprazole ( 20mg bid ) iv omeprazole ( 40mg qd ) three day . The presence recurrent bleed within three day , in-hospital complication duration hospital stay record analyze . At end study , able determine whether patient treated oral rabeprazole iv pantoprazole similar re-bleeding complication rate hospitalization day .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>moderate mild upper gastrointestinal peptic ulcer bleed shock liver cirrhosis uremia severe UGI bleeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>rabeprazole</keyword>
	<keyword>omeprazole</keyword>
	<keyword>upper gastrointestinal bleeding</keyword>
</DOC>